Literature DB >> 2201078

Treatment of sexually transmitted vaginosis/vaginitis.

J G Lossick1.   

Abstract

Although much has been learned about sexually transmissible forms of vaginitis/vaginosis during the past decade, therapeutic options for these disorders remain limited. A single 2-g oral dose of metronidazole still remains highly effective against most Trichomonas vaginalis infections. Mildly resistant infections can usually be cured with metronidazole oral doses of 2 g daily for 3-7 days. When highly resistant infections occur, toxic levels of metronidazole may be needed for the drug to cure the infection. Metronidazole (500 mg twice daily for 7 days) continues to be highly efficacious in the treatment of bacterial vaginosis. Shorter oral treatment regimens that use single 2-g doses of metronidazole for 2-3 days appear promising but may be associated with higher relapse rates. Oral clindamycin (300 mg twice daily) or local 2% clindamycin cream (once daily for 7 days) also may be effective. Metronidazole intravaginal sponges (250-1,000 mg) used for 3 days may also be effective in the treatment of bacterial vaginosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201078     DOI: 10.1093/clinids/12.supplement_6.s665

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

Review 1.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Bacterial vaginosis.

Authors:  C A Spiegel
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

3.  Trichomonas vaginalis genital infections: progress and challenges.

Authors:  Laura H Bachmann; Marcia M Hobbs; Arlene C Seña; Jack D Sobel; Jane R Schwebke; John N Krieger; R Scott McClelland; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

Review 4.  Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis.

Authors:  J C Gillis; L R Wiseman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 5.  Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.

Authors:  Sarah L Cudmore; Kiera L Delgaty; Shannon F Hayward-McClelland; Dino P Petrin; Gary E Garber
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Evaluation of the effect of miltefosine on Trichomonas vaginalis.

Authors:  Débora Afonso Silva Rocha; Ivone de Andrade Rosa; Wanderley de Souza; Marlene Benchimol
Journal:  Parasitol Res       Date:  2013-12-22       Impact factor: 2.289

Review 7.  Evaluation and management of vaginitis.

Authors:  P L Carr; D Felsenstein; R H Friedman
Journal:  J Gen Intern Med       Date:  1998-05       Impact factor: 5.128

Review 8.  Gardnerella vaginalis: characteristics, clinical considerations, and controversies.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 9.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

10.  Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis.

Authors:  D E Nix; R Tyrrell; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.